Mogelijk gemaakt door 
Translate
Translate
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, November 5, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the third quarter of 2020.
| Conference Call & Webcast Details | |
| Date: | Thursday, November 5, 2020 |
| Time: | 5:00 pm Eastern Time |
| Toll Free: | (844) 348-3801 |
| International: | (213) 358-0955 |
| Conference ID: | 9992536 |
| Webcast: | https://edge.media-server.com/mmc/p/b5td2coz |
A live webcast of the conference call can be accessed in the Investors section of Editas Medicine website at https://www.editasmedicine.com/.
About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts:InvestorsMark Mullikin(617) 401-9083mark.mullikin@editasmed.com
MediaCristi Barnett(617) 401-0113cristi.barnett@editasmed.com
